Effective therapy (Rx) in primary hypertension (PH) for 50 years, has featured sympathetic nervous system (SNS) mechanisms. Ganglionic blockers and reserpine were pre-eminent in the 1940s (mydriasis, ileus, impotence, peptic ulcer). Guanethidine, and in the 1960s clonidine and methyldopa, were step II agents to thiazide Rx in the 1950s. Reserpine depletes brain (depression) and peripheral (PPH) noradrenaline (NA) storage sites, guanethidine depleted NA storage via blockade of reuptake. Venomotor sympathoplegia resulted in postural hypertension. An analogue, metaiodobenzyguandine is used in diagnosis and Rx of pheochromocytoma. Clonidine lowers both central and PPH neuronal NA release via both stimulation of ␣ agonist adrenoreceptors (sedation) and specific imadazoline binding sites (IBS). Methyldopa lowers pressure via PPH
Introduction
The sympatholytic and vagolytic effects of the ganglionic blocking agents-such as hexamethonium, were utilised to control blood pressure in the 1940s. Their actions were enhanced by combining them with vasodilators such as hydralazine (Table 1) . 1 However, their vagolytic side effects (constipation, ileus, mydriasis, impotence), often precluded their long-term use. Reserpine, a plant alkaloid from the snake root-Rauwolfia serpentina, largely supplanted the ganglionic blocking agents in the 1950s. Reserpine and the ganglionic blockers could be administered orally and intravenously for patients with mild, severe, and accelerated hypertension. Reserpine depletes catecholamine stores from central and peripheral sympathetic neurons. Their effects are delayed by the oral route, but act within hours after parenteral administration. The lowering of noradrenaline (NA) content in storage sites enhances its synthesis, and thus turnover ( Figure 1 ). 2 The side effects of reserpine that most often lead to its discontinuation are peptic ulcer (vagal imbalance) seen when doses exceed 0.5 mg/day, and depression related to central nervous system amine depletion.
Sympathoplegic agents
Guanethidine, an NA analogue, is taken up into peripheral nerve storage sites, and though NA storage contents are lowered via release onto monoamine oxidase, it is antiadrenergic mainly by preventing NA release into the synapse. An early hypertensive response may be seen. Although the peripheral actions of guanethidine avoid the side effects of depression (ie, reserpine), those of erectile dysfunction, diarrhoea and postural hypertension were often severely debilitating, lasting for as long as a week after discontinuation of therapy. However, an analogue of guanethidine, metaiodobenzylguanidine (MIBG), is very useful clinically as an imaging agent in the localisation of pheochromocytoma. 3 Methyldopa is an analogue of the natural amino acid dihydroxyphenylaline (DOPA) and inhibits the formation of dopamine (DA) by way of aromatic acid decarboxylase from L-DOPA. Methyldopa did not lower blood pressure in animal studies, but was found serendipitously to lower blood pressure in man and became the premier antihypertensive agent S119 One patient discontinued treatment.
Figure 1
Alterations of noradrenaline turnover rate produced by reserpine and pargyline. The biological decay curves during pargyline above, and the curves during reserpine, below, are compared with the average curve of six untreated hypertensive patients. l-dopa-
3
H dose in each case was 15 c/kg. The isotope was administered to GD and AT during the 4th week of pargyline therapy (75 mg/day orally) and to AL and WJ after 5 months and 1 year, respectively, of reserpine (0.25 mg/day orally).
in the 1960s and 1970s. The major mechanism of action of methyldopa is via its conversion to its analogues-alphamethyl DA and alphamethyl NA. The latter is a potent alpha-2 receptor agonist in the medulla thereby reducing central neurogenic tone. Despite the side effects of depression, postural hypotension, retrograde ejaculation and galactorrhoea, methyldopa was utilised as monotherapy or in combination with diuretic therapy for many years. It remained popular in many countries well into the 1980s and in some parts of the world until the 1990s. In the 1980s it was combined with nifediJournal of Human Hypertension pine in some countries, and the advantages of its sympathoplegic effecta were noted with this combination.
Clonidine was introduced into the United States in the early 1960s from Germany, where a congener of naphazoline was developed as a topical agent to constrict nasal blood vessels. Clonidine, an alpha agonist which reduces the release of NA centrally via stimulation of presynaptic alpha-2 receptors, was discovered to be an antihypertensive quite by chance when the principal investigator's receptionist became hypotensive after topical intranasal administration of clonidine. Subsequently, by both the oral route and transdermal application, it remains an effective hypotensive agent. It is a sympathoplegic agent that has both central and peripheral actions, thereby lowering both the content of central or spinal fluid NA as well as plasma NA ( Figure 2) . 4, 5 The side effects of clonidine (dry mouth, initial drowsiness, postural hypotension and 
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Journal of Human Hypertension rebound hypertension) have relegated the drug to 'add-on therapy' to achieve blood pressure control rather than monotherapy. However, its transdermal application increases compliance, improving blood pressure control, and minimising side effects. Unfortunately, 10-20% of patients develop a skin allergy to the adhesive, and eventually may be unable to use the patch.
Beta receptor antagonists
The beta receptor antagonists were introduced from Great Britain by Black in the mid 1960s and became the premier antihypertensive agents, both as monotherapy and in combination with vasodilators well into the 1980s. In general, the beta receptor antagonists are thought to exert their antihypertensive effects in part by blocking beta receptors in the kidney to reduce renin release, by reducing central sympathetic tone, and via stimulating vascular prostacycline synthesis (Table 2 ). Beta receptor antagonists have been found to be cardioprotective and reduce by 40 to 65% the morbidity and mortality of patients with congestive heart failure (CHF), those after myocardial infarction, type II diabetes, and hypertensive patients with renal failure. They are cardioprotective for high coronary risk patients undergoing the gauntlet of surgery. However, they can have adverse effects via glucose intolerance related to both insulin resistance and pancreatic insulin release. They may produce hypertriglyceridaemia and lower high-density lipoprotein in part via inhibition of lipoprotein lipase. On the other hand, these sympatholytic effects prove valuable in patients with high levels of plasma renin and catecholamines who have reductions in plasma catecholamines and proportional reductions in blood pressure after beta receptor antagonists.
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Alpha receptor antagonists
The first alpha blockers developed in the 1950s had potent histaminic effects causing tachycardia and flushing. Phentolamine by both intravenous and oral routes provided rapid alpha blockade without the side effects, but its rapid and evanescent action proved difficult for long-term clinical value. Phentolamine, a nonspecific alpha-1,2 receptor antagonist, given intravenously is a diagnostic test in doses of 2.5 to 10 mg, is useful along with nitroprusside and esmolol in hypertensive crises of patients with pheochromocytoma, and in those with rebound hypertension after abrupt cessation of alpha-2 agonist therapy. In the 1960s, phenoxybenzamine, a nonspecific alpha-1,2 antagonist, in doses of 10 to 40 mg/day, replaced phentolamine as a once a day, long-acting agent for patients with pheochromocytoma and is useful for some patients with renal failure with raised sympathetic tone. A subsequent series of alpha adrenal receptor antagonists were more specific for the alpha-1 receptor, including prazosin, terazosin, and doxazosin. The latter two had longer durations of action and were generally effective in upwards of 40-50% of hypertensives as monotherapy. Doxazosin was effective in blunting the rise in blood pressure produced by both isotonic and isometric exercise. It was less effective in mitigating mental stress induced rises in blood pressure. 7, 8 Strangely, although thought initially to be a phosphodisterase inhibitor and later a specific alpha-1 antagonist, doxazosin increased plasma NA levels in man. 7 The changes in plasma NE levels were not associated with a rise in heart rate. 7 Recent clinical findings of a raised incidence of CHF in the ALLHAT trial patients treated with doxazosin as compared with diuretic therapy, 9 suggest that the rise in NA levels 7 along with sodium and water retention may have been detrimental to cardiac function. Earlier studies in human CHF with prazosin reported lowering of left ventricular diastolic pressure and improved cardiac performance after prazosin in CHF initially, but were not attended by long-term morbidity/mortality benefits after prazosin therapy.
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Labetalol is a hybrid compound sharing both alpha and beta receptor antagonism properties. Labetalol has a greater affinity for beta receptor vs alpha receptor sites. A lack of significant alpha blockade in some patients with pheochromocytoma is thought to account for their exaggerated pressor responses after the administration of this combined alpha and beta receptor antagonist. We found that labetalol reduced the blood pressure responses to hand grip and isometric exercise, 10 and also was effective in blunting the early morning pressure surge in hypertensives associated with the rise plasma NA in the morning after awakening (Figure 3) . 11 In general, the side effects of labetalol, both lassitude due to central effect of the beta blocker, and postural hypotension due to the alpha blocker effects, have relegated it to a lesser role in the treatment of hypertension.
Recently, the alpha and beta blocker, carvedilol, has been found to be very effective in reducing mortality in patients with congestive heart failure. 12 This agent and extended release metoprolol succinate have raised the awareness of the value of beta receptor antagonists as modulators of neural tone in congestive failure, reducing mortality as much as 65% in those patients. 12, 13 Carvedilol and metoprolol have been found to control blood pressure in upwards of 50-60% of hypertensives as monotherapy. They have placed the sympathetic nervous system into pre-eminence along with the reninangiotensin system in cardiovascular disease, and of course specifically and especially, hypertension and CHF. 
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Imidazoline receptor agonists
A more recent centrally acting antihypertensive agent acts on the I 1 imidazoline receptors and lowers central sympathetic nerve discharge without stimulating alpha-2 receptors and the resultant sleep/ sedation side effects. Moxonidine, an I 1 imidazoline agonist lowers blood pressure by its action on rostral ventrolateral medulla inhibiting central sympathetic output to the peripheral vasculature, heart and kidney. Moxonidine in doses of 200 to 400 mg daily reduces blood pressure, plasma catecholamines, and plasma renin activity. 14 Further, moxonidine reduces both sympathetic neural firing and blood pressure responses to cold pressor tests, and isometric handgrip exercise. Although moxonidine was found to inhibit resting sympathetic vasoconstriction tone and sympathetic reflex responses in patients with CHF as well as those with hypertension, in one large trial in CHF, moxonidine failed to reduce mortality. The study was stopped early due to increased morbidity in patients receiving moxinidine.
Calcium channel antagonists
Verapamil, a calcium channel antagonist, was introduced as a beta receptor antagonist in the 1970s, because it had negative chronotropic and inotropic effects. Eventually, verapamil's true identity as a calcium antagonist was uncovered. In general, calcium antagonists reduce the exocytic release of noradrenaline from storage granules, but the rapid hypotensive properties of some dihydropyridines may lead to reflex sympathetic stimulation. Thus, with both verapamil and diltiazem, there may be an initial increase in sympathetic nervous system tone, but shortly thereafter, there is a reduction of noradrenergic tone. 15 On the other hand, the dihydropyridine, nifedipine, appears to yield a reflex increase in neural tone, after both immediate 16 and sustained 17 release preparations. Unlike the other dihydropyridine calcium antagonists, amlodipine appears to have less stimulating properties on the central and peripheral sympathetic nervous system (SNS). The slower binding of the calcium antagonist, amlodipine, to its calcium channel generates a lesser SNS response and in some studies lowered plasma NA. 15 The reflex SNS stimulation produced by the dihydropyridine calcium channel antagonists can be offset by coadministration of either ACE inhibitors or beta receptor antagonists or alpha blockers. These may also enhance the hypotensive effect of the dihydropyridine calcium channel antagonists. In clinical studies, there is evidence for the cardioprotective effects of the sustained release heart rate controlling calcium channel blockers 18 and the dihydropyridine agents. 19 The heart rate lowering calcium channel antagonists may provide more effective cardioprotection than the dihydropyridine calcium channel blockers, related perhaps to the disparity of those neural effects.
Angiotensin-converting enzyme (ACE) inhibitors and AII antagonists
Angiotensin-converting enzyme inhibition in both human and animal studies has been associated with reduction in sympathetic nerve tone, as well as inhibition of the renin-angiotensin-aldosterone system. Hypertensives with higher plasma NA levels have better blood pressure responses to ACE inhibitor therapy. Patients with CHF and higher levels of plasma NA have greater risk and better reductions in mortality, related to NA levels. Studies with the angiotensin II receptor antagonists indicate a sympathoplegic effect similar to that of the ACE inhibitors. 20 In one CHF study ELITE I, Q-T dispersion, a marker of both neural tone and ventricular irritability, was raised in patients treated with the ACE inhibitor, captopril, but not after losartan. The lower rate of death and sudden death rate in ELITE I after losartan-treated patients suggested that the ARB lowered ventricular irritability, 21 but this effect was absent in ELITE II.
Combination therapy
The immediate future for sympathoplegic therapy seems to lie in low dose combination therapy and in refinements of some of the newer therapies. For example, the combination of beta-blocker and hydrochlorothiazide in very low dose, such as bisoprolol 2.5 mg and hydrochlorothiazide 6.25 mg, and combinations of ACE inhibitor and hydrochlorothiazide such as benazepril 5 mg and hydrochlorothiazide 6.25 mg, seem to be as effective as full dose monotherapy with a minimum of sympathoplegic side effects. The efficacy of mini-dose combination may be due in part to lesser perturbation of the autonomic nervous system in responses to the lower dose of the diuretic. Recent analysis of the SHEP trial finished over a decade ago now suggest that the diuretic doses utilised in this trial resulted in hypokalaemia (less than 3.5) prevalence of 7%, compared with 0.7% hypokalaemia seen in the mini-dose combinations. The findings in the SHEP trial suggest that the hypokalaemia and perhaps hypomagnesaemia, obviated the benefit in morbidity and mortality reductions. 22 It is also conceivable that part of the lack of benefit was related to excessive noradrenergic tone in these patients after larger doses of diuretic therapy. The two effects of higher dose diuretic therapy, low potassium and raised NA levels, may have contributed to the cardiovascular mortality seen in these patients.
Combination therapy of an ACE inhibitor or ARB with vasodilators like dihydropyridines should therefore offer particular benefit. Patients with CHF on ACE inhibitor therapy had a further reduction in sympathetic tone when the angiotensin receptor blocker, candesartan or valsartan, was added to their therapy. A newly released ARB, eprosartan, has been found to reduce stimulated NA release in the pith rat model and in one other animal model. It has been proposed that eprosartan, which is the only ARB devoid of the phenylthiazine ring, has a better fit in the presynaptic angiotensin II site which regulates NA release. 23 Studies to corroborate these findings are planned in humans.
Dual metalloprotease inhibitors
Lastly, the newest class of agents to be introduced are a combined metalloprotease inhibitor omapatrilat. This agent lowers blood pressure by interfering with the formation of angiotensin and by preventing the degradation of the vasoactive peptides such as ANP, BNP, bradykinin, and adrenomedulin. ANP and BNP inhibit central SNS tone.
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Summary
There is abundant evidence for the sympathoplegic action of many classes of antihypertensive agents. Those developed in the first three decades of antihypertensive therapy were often too laden with debilitating side effects and hampered their long-term use. The last three decades of antihypertensive agents have yielded drugs with improved efficacy and lower side effects. Monotherapy with alpha receptor agents may be less cardioprotective than combined alpha and beta blockers as found in patients with CHF. Combination therapy offers improved blood pressure control for a majority of hypertensives; employing drugs like ACE inhibitors and ARBs which reduce sympathetic tone in combination with vasodilators like hydralazine, minoxidil, and dihydropyridine calcium blockers, which raise SNS tone. It is likely that in the future, refinements in sympathoplegic therapy will result in improved blood pressure control and further reduction of cardiovascular morbidity and mortality.
